Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017

TheMotleyFool 
0 0 29.11.17
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
 
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017

For Celldex Therapeutics (NASDAQ: CLDX), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017 with investors having both hope and fear. Unfortunately, fear outweighed hope for much of the year.

Celldex stock is down more than 15% so far this year despite several nice rallies during the last 11 months. Here's where things went wrong for the biotech in 2017.

Image source: Getty Images.

Continue reading


Source: Fool.com

Celldex Therapeutics Stock

€41.20
1.480%
There is an upward development for Celldex Therapeutics compared to yesterday, with an increase of €0.60 (1.480%).
With 16 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 61 € shows a positive potential of 48.06% compared to the current price of 41.2 € for Celldex Therapeutics.
Show more
Like: 0
CLDX
Share

Comments

Not a member yet? Sign up for free!